With biotech stocks experiencing a mini renaissance of sorts in recent weeks, many traders were eagerly looking forward to profitable industry bellwether Gilead to set the tone for the next few days and weeks of trading. And while moments ago the company reported Q2 EPS of $3.08, down from $3.15 a year ago, it beat expectations of $3.02 as revenue of $7.77 billion came in line with expectations (down from $8.24 billion a year ago), the reason why the stock is currently sliding after hours is because while the biotech giant did beat, it cut its full year guidance by $500 million on